06:31:18 EDT Tue 04 Oct 2022
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Optimi Health Corp
Symbol OPTI
Shares Issued 70,231,883
Close 2022-06-17 C$ 0.24
Recent Sedar Documents

Optimi asks Health Canada for permission to make MDMA

2022-06-20 10:31 ET - News Release

Mr. Bill Ciprick reports

OPTIMI HEALTH REQUESTS APPROVAL TO MANUFACTURE MDMA, OTHER SYNTHETIC PSYCHEDELICS

Optimi Health Corp. has submitted a request with Health Canada for an amendment to its Controlled Substances Dealer's licence.

The amendment would enable the company to synthesize, process and distribute pharmaceutical-grade 3,4-Methylenedioxymethamphetamine (MDMA), among other substances, at its Princeton, B.C., facility.

With the company's main capital expenditure now completed, it will move to expand its offering to encompass a wide variety of synthetic psychedelics through its market-leading European Union good manufacturing practices cultivation and analytical laboratory. The move aligns with Optimi's planned year of commercialization, allowing the company to maximize revenue-generating opportunities through standardized psychedelic drug testing, research and development, and product development through approved clinical trials and exemption-based applications.

Contiuing large-scale studies, including phase III clinical trials investigating MDMA conducted by the Multidisciplinary Association for Psychedelic Studies (MAPS), along with more recent decriminalization initiatives announced in the province of British Columbia, have generated significant unmet demand for these substances for research purposes.

Optimi Health's chief science officer, Justin Kirkland, stated that: "Since our inception, Optimi has received a steadily increasing volume of inquiries related to the production of synthetic psychedelics from stakeholders within the sector, made all the more timely by recent developments. Our analytical laboratories were purpose-built to enable us to act as an EU-GMP-compliant drug manufacturer for these interests, without in any way detracting from our primary goal of cultivating natural psilocybin."

Mr. Kirkland elevates Optimi as an industry leader utilizing his drug manufacturing expertise shown in his USPTO-awarded Bromo-LSD manufacturing patent sold in 2020 for $10-million and GMP regulatory knowledge from his role as chief executive officer at Food and Drug Administration-registered Fristoe Pharmaceuticals.

Optimi's CEO, Bill Ciprick, says the company's EU-GMP operational footprint and throughput capacity is unmatched in North America and would likely take new entrants into the space years and millions of dollars to meet Optimi's scale and clinical efficiency.

"We have a strong idea of our position in the market and how the amendment fits with our strategic priorities," said Mr. Ciprick. "We are filing this amendment following conversations with researchers and drug developers which have led to a high volume of requests for GMP-compliant synthetic psychedelics. The positive reports from trauma sufferers, including veterans groups, for whom substances such as MDMA might make a difference, mean that safe, scalable supply is going to be more crucial than ever to the success of psychedelic medicine.

"As we continue with our planned year of commercialization, Optimi views the capacity to produce and distribute these substances as integral to our overall positioning and revenue generation within the sector's supply chain," Mr. Ciprick concluded.

The company's amendment application to Health Canada also includes:

N,N-Dimethyltryptamine ("DMT");

  • 3,4,5-trimethoxyphenethylamine (Mescaline);
  • 2-(2-chlorophenyl)-2-(methylamino)cyclohexanone (Ketamine);
  • Lysergic Acid Diethylamide (LSD);
  • 1-(1-phenylcyclohexyl)piperidine (Phencyclidine);
  • 4-Hydroxybutanoic Acid (GHB);
  • 4,9-dihydro-7-methoxy-1-methyl-3H-pyrido(3,4-b)indole (Harmaline);
  • 4,9-dihydro-1-methyl-3H-pyrido(3,4-b)indol-7-ol (Harmalol);
  • Salvia Divinorum, Salvinorin A;
  • 4-Bromo-2,5-Dimethoxybenzeneethanamine (2C-B).

About Optimi Health Corp.

Optimi is a homegrown, Canadian success story producing and supplying natural, EU-GMP-grade psilocybin and functional mushrooms that focus on the health and wellness markets. Built with the purpose of producing scalable, natural mushroom formulations for transformational human experiences, the company's goal is to be the No. 1 trusted, compassionate supplier of safe, natural EU-GMP psilocybin throughout the world. With a vertically integrated approach, Optimi is engaged in the cultivation, extracting, processing and distribution of high-quality functional and psychedelic mushroom products at its two facilities comprising a total of 20,000 square feet in Princeton, B.C.

We seek Safe Harbor.

© 2022 Canjex Publishing Ltd. All rights reserved.